Multiple sclerosis. Part 2: ophthalmic issues in MS therapy
Related Experiment Video
Updated: Jun 19, 2026

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
Published on: April 14, 2014
1University of Chicago, Department of Neurology, Chicago, Illinois 60637, USA. John.Pula@uchospitals.edu
Purpose Of Review:
This update includes topics relating to the treatment of multiple sclerosis (MS) for the ophthalmologist.
Recent Findings:
Despite investigation into numerous genetic and environmental factors, the cause of MS remains elusive. MS is a disease of the central nervous system that mainly affects young people and usually progresses over time, leading to disability in multiple areas, including mobility, cognition, affect and vision. It is likely that, as novel MS treatments are introduced, there will be a greater interest in tracking visual function and monitoring for visual complications.
Summary:
Current therapies in MS include interferon, glatiramer, natalizumab and mitoxantrone. Other MS treatments are imminent, and include oral medications, monoclonal antibodies and chemotherapy. Treatment of the visual symptoms in MS and the side effects of MS therapies are reviewed in this article.
Related Concept Videos
Multiple Sclerosis l: Introduction
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Ophthalmic Drug Delivery Systems
Glaucoma: Overview
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...